Recursion Pharmaceuticals, Inc.
RXRX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$3.80
KIRA · Stoqly’s AI analyst, in plain words
- Recursion Pharmaceuticals, Inc. had $74.7M of revenue in fiscal 2025, up 26.9% on the year before. Over five years, revenue changed +79.9% a year on average.
- Its operating margin was −867.9%, down 53.8 pts: of every 100 in sales, about −868 is left after running the business.
- Recursion Pharmaceuticals, Inc. lost $645M in fiscal 2025.
- Free cash flow was −$378M in fiscal 2025, −506.5% of revenue.
- Recursion Pharmaceuticals, Inc. has $706M more cash than debt.
Market cap
$2.0B
P/E
—
Revenue
$74.7M
Net income
−$645M
Free cash flow
−$378M
Operating margin
−867.9%
Recursion Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+26.9%
Yes. Sales grew 26.9% last year.
Does it make a profit?
−863.4%
No. It lost money last year.
Does profit turn into cash?
−506.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Recursion Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- RECURSION PHARMACEUTICALS, INC.
- CIK
- 0001601830
Recursion Pharmaceuticals, Inc. · RXRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Revenue growth | 156.9% | 291.5% | 11.9% | 32.0% | 26.9% |
| Gross margin | 100.0% | −21.2% | 4.5% | 23.1% | 5.0% |
| Operating margin | −1,795.8% | −616.7% | −785.3% | −814.1% | −867.9% |
| Net income | −$186M | −$239M | −$328M | −$464M | −$645M |
| Net margin | −1,832.2% | −601.0% | −736.0% | −788.0% | −863.4% |
| Diluted EPS | −$1.49 | −$1.36 | −$1.58 | −$1.69 | −$1.44 |
| Cash | |||||
| Cash from operations | −$159M | −$83.5M | −$288M | −$359M | −$372M |
| Capital expenditure | $39.8M | $37.1M | $12.0M | $13.7M | $6.5M |
| Free cash flow | −$198M | −$121M | −$300M | −$373M | −$378M |
| FCF margin | −1,949.4% | −302.6% | −672.4% | −633.7% | −506.5% |
| Share count change | 475.5% | 40.0% | 18.4% | 31.9% | 63.2% |
| Debt and strength | |||||
| Cash and short-term investments | $517M | $550M | $392M | $594M | $743M |
| Debt incl. finance leases | $0.7M | — | $1.1M | $54.1M | $37.0M |
| Shareholders' equity | $543M | $486M | $463M | $1.0B | $1.1B |
| Current ratio | 11.5x | 5.7x | 4.7x | 3.8x | 5.5x |
| Interest coverage | −61.9x | −4,467.8x | −3,608.9x | −304.7x | −358.1x |
| Returns and quality | |||||
| Return on capital | −532.8% | — | −378.8% | −80.9% | −126.0% |
| Return on equity | −110.8% | −46.6% | −69.1% | −61.9% | −59.5% |
| Return on tangible equity | −34.5% | −49.5% | −87.5% | −84.3% | −97.9% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 4 |
| Altman Z'' | 9.6 | 1.4 | −2.4 | −0.4 | −1.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$7.7M
6 insiders
Of sales under plans
100%
$7.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Recursion Pharmaceuticals, Inc. · RXRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.80 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0001601830). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.